Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present) [0.03%]
ALK5抑制剂专利回顾(2013-现在)
Xin-Yi Huang,Chao-Qun Yu,Xin Wang et al.
Xin-Yi Huang et al.
Introduction: Activin receptor-like kinase 5 (ALK5) is a pivotal component of the transforming growth factor β (TGF-β) signaling pathway. Currently, 10 ALK5 inhibitors are under clinical investigation, with numerous oth...
A patent review of VEGFR-2 inhibitors: an update (2022 - present) [0.03%]
VEGFR-2抑制剂专利分析：更新版(2022年至今)
Thoraya A Farghaly,Marwa F Harras,Amani M R Alsaedi et al.
Thoraya A Farghaly et al.
Introduction: A complicated process called angiogenesis creates new blood vessels from existing ones. Oxygen and nutrients from angiogenesis support tumor development, invasion, and metastasis. Many biological agents caus...
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present) [0.03%]
2023年至今NLRP3炎症小体抑制剂专利分析进展
Jannatun N Namme,Yiming Xu,Elijah McClendon et al.
Jannatun N Namme et al.
Introduction: With increasing knowledge and understanding of the molecular mechanisms of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and its role in inflammatory diseases, NLRP3 has emerged...
Patent landscape and therapeutic evolution of Mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes [0.03%]
玛珠肽治疗肥胖和2型糖尿病的专利布局与机制演化——一种GLP-1/胰高血糖素受体激动剂药物
Mohammed Abdul Fasi
Mohammed Abdul Fasi
Introduction: Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its cli...
An updated patent review of isoflavones and isocoumarins (2018-2024) [0.03%]
异黄酮和异香豆素专利回顾更新(2018-2024)
Hidayat Hussain
Hidayat Hussain
Introduction: It is well established that isocoumarins and isoflavones exhibit intriguing biological effects. During the period 2018-2024 isocoumarins and isoflavones chemistry has attracted attention due to their biologi...
5'-ectonucleotidase (CD73) inhibitors: a patent review (2021-present) [0.03%]
5'-核苷酸外酶（CD73）抑制剂专利回顾（2021至今）
Zhaolin Wang,Anna Junker
Zhaolin Wang
Introduction: Adenosine-mediated immunosuppression is a major mechanism of tumor immune escape and is largely driven by ecto-5'-nucleotidase (CD73), which catalyzes the formation of extracellular adenosine and limits the ...
LSD1 inhibitors for anticancer therapy: an updated patent review (2022-2025) [0.03%]
抗癌治疗中的 LSD1 抑制剂专利回顾（2022-2025）
Zhoudong Zhang,Jiyu Li,Zitong Wang et al.
Zhoudong Zhang et al.
Introduction: Lysine-specific demethylase 1 (LSD1) is a key epigenetic enzyme relying on flavin adenine dinucleotide to regulate gene expression via histone H3 demethylation and non-histone substrate modification. Discove...
Patents involving monoamine oxidase (MAO): a comprehensive update (2022-2025) on its inhibitors and applications [0.03%]
涉及单胺氧化酶(MAO)的专利：其抑制剂和应用的全面更新(2022-2025)
Moataz A Shaldam,Simone Carradori,Marwa Balaha et al.
Moataz A Shaldam et al.
Introduction: Monoamine oxidases (MAOs) A and B are key enzymes for the oxidative deamination of monoamine neurotransmitters, including dopamine, serotonin, norepinephrine, and tyramine. Selective MAO-B inhibitors are cli...
Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present) [0.03%]
最近的因子XII(a)抑制剂研究进展：2020年至今的专利布局更新
Dmitrii V Kalinin
Dmitrii V Kalinin
Introduction: Factor XII (FXII) is a liver-derived plasma zymogen that autoactivates on anionic surfaces to FXIIa, which drives the contact blood coagulation pathway, kallikrein-kinin signaling, fibrinolysis, and classica...
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: updated patent review (2019-2023) [0.03%]
蛋白酪氨酸磷酸酶1B(PTP1B)抑制剂作为潜在的抗糖尿病药物：2019-2023年专利回顾更新
Rafia Ashfaq,Hidayat Hussain
Rafia Ashfaq
Introduction: Inhibition of protein tyrosine phosphatase 1B (PTP1B) is a key strategy for improving insulin sensitivity in various cells. This strategy is supported by human genetic data. PTP1B inhibitors are considered a...